Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol for Crohn's disease (C87069)
NCT00358683Phase 3Withdrawn
- Sponsor
- UCB
- Start
- Nov 2007
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Primary endpoint: Opportunity to receive treatment until drug availability. Planned start Nov 2007; status: withdrawn.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00358683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00358683.